Shattuck Labs Upgraded to Buy Rating by Wall Street Firm

Analysts see growth potential for biotech company's opioid addiction treatment pipeline

Mar. 28, 2026 at 5:33am

Got story updates? Submit your updates here. ›

Shattuck Labs (NASDAQ:STTK), a clinical-stage biotech company focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, has been upgraded from a 'hold' to a 'buy' rating by analysts at Wall Street Zen. The upgrade comes as Shattuck Labs continues to advance its lead program targeting the synthetic opioid fentanyl, which has been responsible for a significant proportion of overdose fatalities.

Why it matters

The upgrade from Wall Street Zen is a positive sign for Shattuck Labs, whose innovative approach to tackling the opioid crisis through immunotherapeutic vaccines could have a significant impact if successful. As the opioid epidemic continues to devastate communities across the country, new treatment options are desperately needed, and Shattuck Labs' pipeline holds promise.

The details

In their research note, the analysts at Wall Street Zen cited Shattuck Labs' progress in advancing its lead fentanyl-targeting program, as well as the company's broader pipeline of substance use disorder treatments. The analysts also pointed to Shattuck Labs' strong financial position, with the company having raised significant capital to support its research and development efforts.

  • Wall Street Zen issued the upgrade on Saturday, March 28, 2026.
  • Shattuck Labs' stock (NASDAQ:STTK) closed at $6.02 on Friday, March 27, 2026, down 4.6% for the day.

The players

Wall Street Zen

A financial research and analysis firm that provides investment recommendations to its clients.

Shattuck Labs

A clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids.

Got photos? Submit your photos here. ›

What they’re saying

“We believe Shattuck Labs' innovative approach to tackling the opioid crisis through immunotherapeutic vaccines holds significant promise, and we are upgrading the stock to a 'buy' rating based on the company's progress and strong financial position.”

— Wall Street Zen Analyst

What’s next

Investors will be closely watching Shattuck Labs' progress as the company continues to advance its lead fentanyl-targeting program and its broader pipeline of substance use disorder treatments. The company's upcoming clinical trial results and regulatory milestones will be key catalysts for the stock.

The takeaway

Shattuck Labs' upgrade to a 'buy' rating by Wall Street Zen highlights the growing interest and optimism around the company's innovative approach to addressing the opioid epidemic. As the search for effective treatments continues, Shattuck Labs' immunotherapeutic vaccines could play a crucial role in helping to save lives and reduce the devastating impact of substance use disorders.